Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 25, 2024

Identifying Social Determinants of Health in Cardiovascular Care

Medical experts emphasize the importance of partnering with community leaders to address social determinants of health that act as barriers to care.

Episodes in this series

EP. 1 Disparities in Cardiovascular Care for Diverse Populations

EP. 1 Disparities in Cardiovascular Care for Diverse Populations

EP. 2 Innovation vs Access: Supporting Underserved Communities

EP. 2 Innovation vs Access: Supporting Underserved Communities

EP. 3 Exploring Polypharmacy: Adherence, Communication, and Outcomes

EP. 3 Exploring Polypharmacy: Adherence, Communication, and Outcomes

EP. 4 Gender-Based Disparities in Cardiovascular Disease

EP. 4 Gender-Based Disparities in Cardiovascular Disease

Video 5 - "Peripheral Arterial Disease Awareness for Minority Populations"

EP. 5 Peripheral Arterial Disease Awareness for Minority Populations

Video 6 - "Community Partnership: Increasing Public Awareness of CVD"

EP. 6 Community Partnership: Increasing Public Awareness of CVD

Video 6 - "Community Partnership: Increasing Public Awareness of CVD"

EP. 7 Recent Data Reveals Disparities in Cardiovascular Care

Video 6 - "Community Partnership: Increasing Public Awareness of CVD"

EP. 8 Identifying Social Determinants of Health in Cardiovascular Care

Video 9 - "Impact of Novel Medications and Out-Of-Pocket Costs in Managing Cardiovascular Disease"

EP. 9 Impact of Novel Medications and Out-Of-Pocket Costs in Managing Cardiovascular Disease

video 10 - "Developing Practical Solutions to Improve Cardiovascular Care"

EP. 10 Developing Practical Solutions to Improve Cardiovascular Care

video 10 - "Developing Practical Solutions to Improve Cardiovascular Care"

EP. 11 Advancing Cardiovascular Care Through Technological Innovation

video 10 - "Developing Practical Solutions to Improve Cardiovascular Care"

EP. 12 Desired Technology Innovations to Prevent Cardiovascular Disease

Video 13 - "Measuring Implicit Bias"

EP. 13 Measuring Implicit Bias

Video 14 - "Achieving Equitable Representation in Clinical Studies"

EP. 14 Achieving Equitable Representation in Clinical Studies

Video 15 - "Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion"

EP. 15 Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

CRC animation | Image Credit: Thipphaphone - stock.adobe.com

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

ByBrooke McCormick

June 26th 2026

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Trending on AJMC

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Health Equity & Access Weekly Roundup: June 26, 2026

ATTR-CM Incidence, Prevalence Rose Sharply in the US